Porphyrin and phthalocyanine antiscrapie compounds

Science

Volumn 287, Issue 5457, 2000, Pages 1503-1506

  Priola, Suzette A ^a   Raines, Anne ^a   Caughey, Winslow S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEUTEROPORPHYRIN IX 2,4 BIS(ETHYLENE GLYCOL) IRON; PHTHALOCYANINE DERIVATIVE; PORPHYRIN DERIVATIVE; PRION PROTEIN; TETRA(4 N METHYLPYRIDYL)PORPHINE IRON III; TETRASULFOPHTHALOCYANINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; INCUBATION TIME; MOUSE; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; SCRAPIE; SURVIVAL TIME; TRANSGENIC MOUSE;

ANIMALS; BRAIN; CRICETINAE; DEUTEROPORPHYRINS; DISEASE PROGRESSION; FERRIC COMPOUNDS; INDOLES; METALLOPORPHYRINS; MICE; MICE, TRANSGENIC; PORPHYRINS; PRPSC PROTEINS; SCRAPIE; SPLEEN; TIME FACTORS;

ANIMALIA; BOVINAE; MUS MUSCULUS;

EID: 0034711993     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.287.5457.1503     Document Type: Article

References (31)

1. R. G. Will et al., Lancet 347, 921 (1996).
2. J. Collinge, K. C. L. Sidle, J. Meads, J. Ironside, A. F. Hill, Nature 383, 685 (1996); G. J. Raymond et al., Nature 388, 285 (1997); M. E. Bruce et al., Nature 389, 498 (1997).
3. J. Collinge, K. C. L. Sidle, J. Meads, J. Ironside, A. F. Hill, Nature 383, 685 (1996); G. J. Raymond et al., Nature 388, 285 (1997); M. E. Bruce et al., Nature 389, 498 (1997).
4. J. Collinge, K. C. L. Sidle, J. Meads, J. Ironside, A. F. Hill, Nature 383, 685 (1996); G. J. Raymond et al., Nature 388, 285 (1997); M. E. Bruce et al., Nature 389, 498 (1997).
5. R. G. Will et al., Lancet 353, 979 (1999).
6. B. Caughey and R. E. Race, J. Neurochem. 59, 768 (1992); B. Caughey, D. Ernst, R. E. Race, J. Virol. 67, 6270 (1993).
7. B. Caughey and R. E. Race, J. Neurochem. 59, 768 (1992); B. Caughey, D. Ernst, R. E. Race, J. Virol. 67, 6270 (1993).
8. B. W. Caughey et al., Biochemistry 30, 7672 (1991); K.-M. Pan et al., Proc. Natl. Acad. Sci. U.S.A. 90, 10962 (1993).
9. B. W. Caughey et al., Biochemistry 30, 7672 (1991); K.-M. Pan et al., Proc. Natl. Acad. Sci. U.S.A. 90, 10962 (1993).
10. R. Bonnett, Chem. Soc. Rev. 24, 19 (1995); D. Dolphin, Ed., The Porphyrins (Academic Press, New York, 1978).
11. R. Bonnett, Chem. Soc. Rev. 24, 19 (1995); D. Dolphin, Ed., The Porphyrins (Academic Press, New York, 1978).
12. W. S. Caughey, L. D. Raymond, M. Horiuchi, B. Caughey, Proc. Natl. Acad. Sci. U.S.A. 95, 12117 (1998).
13. 0/0 background (19). Thus, Tg7 mice do not express endogenous mouse PrP-sen but express high levels of hamster PrP-sen in a wide variety of tissues including brain. Because Tg7 mice have substantially shorter disease incubation times than Syrian hamsters when infected with hamster 263K scrapie either IP (about 82 days compared with 120 days) or intracranially (about 45 days compared with 75 days), they were used to test the therapeutic potential of the porphyrins and phthalocyanines.
14. 3+ was dissolved at a concentration of 30 mg/ml in 100% DMSO and stored as a stock solution at room temperature.
15. 3+ was dissolved in 100% DMSO, a group of infected animals was treated with 100% DMSO IP with the same treatment regimen to control for any effect of DMSO on disease progression. All results were analyzed with the unpaired student's t test. Animals were monitored for clinical signs and killed when in the terminal phases of disease. To confirm the diagnosis of scrapie, we removed the brain and spleen and analyzed them by Western blot with the hamster PrP-specific antibody 3F4 for the presence of PrP-res as described previously (18).
16. S. A. Priola, A. Raines, W. S. Caughey, unpublished data.
17. Experiments in progress at the time of publication indicate that when PcTS treatment of Tg7 mice is initiated at 14 or 28 days before infection, disease is delayed by at least several weeks, suggesting that PcTS can be used prophylactically (11).
18. H. Fraser and A. G. Dickinson, Nature 226, 462 (1970); J. Comp. Pathol. 88, 563 (1978).
19. H. Fraser and A. G. Dickinson, Nature 226, 462 (1970); J. Comp. Pathol. 88, 563 (1978).
20. D. R. Borchelt, M. Scott, A. Taraboulos, N. Stahl, S. B. Prusiner, J. Cell Biol. 110, 743 (1990); B. Caughey and G. J. Raymond, J. Biol. Chem. 266, 18217 (1991).
21. D. R. Borchelt, M. Scott, A. Taraboulos, N. Stahl, S. B. Prusiner, J. Cell Biol. 110, 743 (1990); B. Caughey and G. J. Raymond, J. Biol. Chem. 266, 18217 (1991).
22. D. A. Kociskco et al., Nature 370, 471 (1994).
23. M. Pocchiari, S. Schmittinger, C. Masullo, J. Gen. Virol. 68, 219 (1987); R. Demaimay et al., J. Gen. Virol. 75, 2499 (1994); F. Tagliavini et al., Science 276, 1119 (1997).
24. M. Pocchiari, S. Schmittinger, C. Masullo, J. Gen. Virol. 68, 219 (1987); R. Demaimay et al., J. Gen. Virol. 75, 2499 (1994); F. Tagliavini et al., Science 276, 1119 (1997).
25. M. Pocchiari, S. Schmittinger, C. Masullo, J. Gen. Virol. 68, 219 (1987); R. Demaimay et al., J. Gen. Virol. 75, 2499 (1994); F. Tagliavini et al., Science 276, 1119 (1997).
26. S. Sassa, Curr. Med. Chem. 3, 273 (1996); B. Paquette and J. E. van Lier, in Photodynamic Therapy, B. W. Henderson and T. J. Dougherty, Eds. (Dekker, New York, 1992), pp. 145-156.
27. S. Sassa, Curr. Med. Chem. 3, 273 (1996); B. Paquette and J. E. van Lier, in Photodynamic Therapy, B. W. Henderson and T. J. Dougherty, Eds. (Dekker, New York, 1992), pp. 145-156.
28. R. E. Race et al., Neuron 15, 1183 (1995).
29. A. J. Raeber et al., EMBO J. 16, 6057 (1997); J. C. Manson et al., Mol. Neurobiol. 8, 121 (1994).
30. A. J. Raeber et al., EMBO J. 16, 6057 (1997); J. C. Manson et al., Mol. Neurobiol. 8, 121 (1994).
31. We thank B. Chesebro, K. Hasenkrug, and B. Caughey for their suggestions and critiques of this manuscript. Tg7 mice were derived at the Scripps Research Institute in collaboration with the laboratory of M. B. A. Oldstone with support from NIH grant AGO4342.